Reuters logo
BRIEF-Prima BioMed says clinical studies of IMP321 are progressing well​
2017年6月26日 / 上午10点42分 / 3 个月前

BRIEF-Prima BioMed says clinical studies of IMP321 are progressing well​

June 26 (Reuters) - Prima Biomed Ltd

* Operational update

* Says ‍is pleased to advise that clinical studies of IMP321 are progressing well​

* Says ‍final results of 15 patients from safety run-in phase of aipac are expected in q4 of 2017​

* Says ‍data from three cohorts related to the tacti-mel trial​ is expected in h1 2018 Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below